C12Y 304/21072
Iga-specific serine endopeptidase
Official title: IgA-specific serine endopeptidase (3.4.21.72)
C12Y304/21072 (Iga-specific serine endopeptidase) appears on 2 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 11
- Assignees
- 8
- Inventors
- 16
- Latest grant
- 15 Feb 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 2 |
| 2019 | 0 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins15 Feb 2022US 11,248,219 B2Allergan, Inc.
- Non-cytotoxic protein conjugates10 Dec 2013US 8,603,779 B2Allergan, Inc.
- Fusion proteins comprising truncated forms of iga protease and uses thereof17 Sep 2026US 2026/0275321 A1Peking University First Hospital
- Truncated forms of iga protease, fusion proteins comprising a truncated form of iga protease and uses thereof31 Jul 2025US 2025/0242002 A1Peking University First Hospital
- Fusion proteins and methods for treating, preventing or ameliorating pain10 Oct 2019US 2019/0309277 A1Allergan, Inc.
- Target recognition motifs and uses thereof3 Oct 2019US 2019/0300870 A1Massachusetts Institute of Technology
- Suppression of itch18 Oct 2018US 2018/0298367 A1Ipsen Bioinnovation Limited
Most cited
By later US patents